Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies

被引：10

作者：

Zaja, Francesco ^{[1
]}

Federico, Massimo ^{[2
]}

Vitolo, Umberto ^{[3
]}

Zinzani, Pier Luigi ^{[4
]}

机构：

[1] Azienda Osped Univ SM Misericordia, DISM, Ctr Trapianti & Terapie Cellulari Carlo Melzi, Clin Ematol, I-33100 Udine, Italy

[2] Univ Modena & Reggio Emilia, Dipartimento Med Lab Clin & Sanita Pubbl, Modena, Italy

[3] Azienda Osped Citta Salute & Sci Torino, Turin, Italy

[4] Univ Bologna, Inst Hematol L eA Seragnoli, Bologna, Italy

来源：

LEUKEMIA & LYMPHOMA | 2014年 / 55卷 / 05期

关键词：

Mantle cell lymphoma; second-line treatment; targeted therapies; BENDAMUSTINE PLUS RITUXIMAB; NON-HODGKINS-LYMPHOMA; MULTICENTER PHASE-II; PROTEASOME INHIBITOR BORTEZOMIB; ANTI-CD20; MONOCLONAL-ANTIBODY; NERVOUS-SYSTEM INVOLVEMENT; NATIONAL-CANCER-INSTITUTE; SINGLE-AGENT TEMSIROLIMUS; INDOLENT B-CELL; AGGRESSIVE LYMPHOMA;

D O I：

10.3109/10428194.2013.825903

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite recent advances in therapeutic strategies, a large proportion of patients with mantle cell lymphoma (MCL) experience progression after first-line treatment. Several attempts have been made to assess the role of different therapies for the treatment of patients with relapsed/refractory mantle cell lymphoma; however, a consensus on the optimal therapeutic strategy for each individual patient has not been reached. Overall, clinical evidence from phase II studies shows that high-dose cytarabine containing regimens, stem cell transplant and different biological agents all have promising activity with acceptable safety profiles. Therefore, these therapies can represent suitable treatment options for patients with relapsed/refractory MCL. Among different biological agents, at present only temsirolimus has been tested in a phase III study. This review considers available evidence on the management of relapsed/refractory MCL as discussed during a consensus meeting on the current treatment strategies for MCL.

引用

页码：988 / 998

页数：11

共 81 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2] Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group [J].

Ansell, Stephen M. ;

Inwards, David J. ;

Rowland, Kendrith M., Jr. ;

Flynn, Patrick J. ;

Morton, Roscoe F. ;

Moore, Dennis F., Jr. ;

Kaufmann, Scott H. ;

Ghobrial, Irene ;

Kurtin, Paul J. ;

Maurer, Matthew ;

Allmer, Christine ;

Witzig, Thomas E. .

CANCER, 2008, 113 (03) :508-514

[3] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study [J].

Ansell, Stephen M. ;

Tang, Hui ;

Kurtin, Paul J. ;

Koenig, Patricia A. ;

Inwards, David J. ;

Shah, Keith ;

Ziesmer, Steven C. ;

Feldman, Andrew L. ;

Rao, Radha ;

Gupta, Mamta ;

Erlichman, Charles ;

Witzig, Thomas E. .

LANCET ONCOLOGY, 2011, 12 (04) :361-368

[4] Mantle cell lymphoma: A clinicopathologic study of 80 cases [J].

Argatoff, LH ;

Connors, JM ;

Klasa, RJ ;

Horsman, DE ;

Gascoyne, RD .

BLOOD, 1997, 89 (06) :2067-2078

[5] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma [J].

Baiocchi, Robert A. ;

Alinari, Lapo ;

Lustberg, Mark E. ;

Lin, Thomas S. ;

Porcu, Pierluigi ;

Li, Xiaobai ;

Johnston, Jeffrey S. ;

Byrd, John C. ;

Blum, Kristie A. .

CANCER, 2011, 117 (11) :2442-2451

[6] A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150 [J].

Belch, A. ;

Kouroukis, C. T. ;

Crump, M. ;

Sehn, L. ;

Gascoyne, R. D. ;

Klasa, R. ;

Powers, J. ;

Wright, J. ;

Eisenhauer, E. A. .

ANNALS OF ONCOLOGY, 2007, 18 (01) :116-121

[7] Update on the molecular biology of mantle cell lymphoma [J].

Bertoni, F ;

Rinaldi, A ;

Zucca, E ;

Cavalli, F .

HEMATOLOGICAL ONCOLOGY, 2006, 24 (01) :22-27

[8]

Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO

[9]

2-Z

[10]

Camara-Clayette V, 2012, EXPERT REV ANTICANC, V12, P1205, DOI [10.1586/era.12.99, 10.1586/ERA.12.99]

← 1 2 3 4 5 6 7 8 9 →